高血糖患者下颌后牙固定修复中3.3mm与4.1mm亲水钛锆种植体的分层随机对照试验
本研究将高血糖患者按HbA1c分层(5.8%-<7.0% vs ≥7.0%),随机接受⌀3.3mm或⌀4.1mm亲水钛锆种植体支持的下颌后牙固定修复体。12个月时两组边缘骨水平变化无显著差异,⌀4.1mm组种植体稳定性更高,HbA1c≥7%者边缘骨吸收≥0.5mm的 odds 约高7倍。
要点
- ⌀3.3mm与⌀4.1mm钛锆种植体12个月边缘骨水平变化无显著差异。
- ⌀4.1mm种植体稳定性(ISQ)显著更高,⌀3.3mm早期愈合更好。
- HbA1c≥7%者边缘骨吸收≥0.5mm的风险约高7倍。
核心结论
- 1年时⌀3.3mm与⌀4.1mm亲水钛锆种植体边缘骨水平变化无统计学显著差异,⌀4.1mm种植体稳定性更高。
研究设计与样本
- stratified随机对照试验,按HbA1c(5.8%-<7.0% vs ≥7.0%)分层,纳入88例受试者,83例(166枚种植体)完成评估。
主要发现
- 种植体存活率100%,无种植体周围炎。
- 12个月时⌀3.3mm组边缘骨水平变化0.27mm(IQR 0.07-0.68),⌀4.1mm组0.27mm(IQR -0.04至0.54),p=0.078。
- HbA1c≥7%者边缘骨水平变化≥0.5mm的 odds 约高7倍。
- ⌀4.1mm组继发ISQ显著更高(79.6 vs 76.1,p<0.001),⌀3.3mm组早期愈合更好(p=0.005)。
- 咀嚼能力从基线至12个月显著改善,不受种植体直径或HbA1c分层影响(p<0.0001)。
临床怎么用
- 在高血糖患者下颌后牙固定修复中,⌀3.3mm与⌀4.1mm钛锆种植体均可获得良好短期结局。
- 对HbA1c≥7%的患者应关注更高的边缘骨吸收风险,加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare ⌀3.3 mm and ⌀4.1 mm hydrophilic titanium-zirconium implants supporting fixed dental prostheses (FDPs) in mandibular distal-extension situations among participants with varying degrees of hyperglycaemia. MATERIALS AND METHODS: Participants were stratified according to HbA1c (5.8%-< 7.0% vs. ≥ 7.0%) and subsequently randomized within each stratum to receive either ⌀3.3 mm or ⌀4.1 mm titanium-zirconium implants. Each participant received a two-implant-supported multi-unit FDP. The primary outcome was marginal bone level (MBL) change at 12 months after prosthesis delivery. Secondary outcomes included implant stability quotient (ISQ), peri-implant indices, Healing Index and patient-reported outcomes. RESULTS: Of 88 enrolled participants, 83 (166 implants) were evaluated. Implant survival was 100%, with no peri-implantitis. At 12 months, MBL did not differ significantly between the ⌀3.3 mm [0.27 mm (IQR, 0.07-0.68)] and ⌀4.1 mm groups [0.27 mm (IQR, -0.04 to 0.54); p = 0.078]. Participants with HbA1c ≥ 7% had approximately sevenfold higher odds of MBL ≥ 0.5 mm than those with HbA1c < 7%. Secondary ISQ was significantly higher with ⌀4.1 mm implants (79.6 vs. 76.1; p < 0.001), whereas early healing was better with ⌀3.3 mm implants (p = 0.005). Chewing ability improved significantly from baseline to 12 months irrespective of implant diameter or HbA1c category (p < 0.0001). CONCLUSION: At 1 year, ⌀3.3 mm and ⌀4.1 mm hydrophilic Ti-Zr implants demonstrated no statistically significant difference in MBL although ⌀4.1 mm implants demonstrated higher stability. Patient-reported chewing ability improved substantially following rehabilitation for both implant diameters. Higher HbA1c was associated with greater odds of clinically relevant MBL. TRIAL REGISTRATION: The trial was registered prospectively with the Clinical Trials Registry-India (CTRI/2017/08/009315).
引用
- Ebenezer S, Viswanath S, Ramanathan C, et al. Stratified Randomized Controlled Trial of ∅3.3 mm Versus ∅4.1 mm Hydrophilic Titanium-Zirconium Implants Supporting Posterior Mandibular Fixed Prostheses in Hyperglycaemic Subjects. Clin Oral Implants Res. 2026. PMID: 42786568. doi:10.1111/clr.70175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。